CTIBIOTECH

  • Home
  • Company
    • Mission
    • Key Points
    • Key Staff
    • Structural Partners
    • Public Engagement
    • Education
    • Recruitment
    • Laboratory
  • Technology
    • Cancer
    • IMODI
    • Adult Stem Cell Technology Platforms
    • In vitro tox & drug testing
    • Dermatocosmetics / Skin
    • Clinical trials development
    • Biobanking
    • Medical Device R&D
    • Strategic R&D Partners
  • Services
    • Products
      • Tissues and cells
      • Cancer cells
    • Contract testing
    • Medical device
    • Consultancy
    • Our Clients
    • IMODI Products
  • Investors / Media
    • Why we are different
    • News
    • Resources
    • Legal
  • 会社案内
    • 設立 主旨
    • 基盤技術
    • 実績
    • 提供するサービス
    • パートナー
    • 体制
    • 資本
    • パブリケーション
    • サポート
  • Contact

Adult Stem Cell Technology Platforms

CD34+ Stem Cell
CD34+ Stem Cell
Since the 1980’s researchers at CTIBIOTECH have always been at the forefront of what is now called Regenerative Medicine. Experts in harvesting, manipulation, differentiation and development of human tissues from stem cell and progenitor cell tissues, they have published widely in this field, been involved in clinical trials and patented commercially available work.
Stem cells can be harvested from the following sources:
SCs
CTIBIOTECH only uses Adult and Neonatal sources. Primary embryonic tissues are not used and are not researched at CTIBIOTECH
The founders of CTIBIOTECH, Colin McGuckin and Nico Forraz were the first in the world to create liver-like tissue from adult stem cells, using umbilical cord blood as the source of stem cells. They have also produced many different tissue types from adult and neonatal cell sources including:
Tissues
CTIBIOTECH has capabilities in the following areas:
Stem Cell Procurement
OD CBharvest
Gravity-based cord blood collection after birth

From the initial source CTIBIOTECH has experience of:

  • Peripheral blood
  • Umbilical cord blood
  • Placental tissues
  • Umbilical cord wharton’s jelly
  • Amnion
  • Amniotic fluid
  • Bone marrow
  • Skin
  • Adipose
NeedleCB
Umbilical Cord
CBbag
Cord Blood Sample

Collection of samples at sterile grade


Stem Cell Harvesting
CTIBIOTECH has developed specific systems for stem cell harvesting from different tissue sources. We have also assisted both academic and company groups to develop, refine, patent, CE mark and FDA-approve several stem cell harvesting systems.
An example of this can be found here
IMG_0158
Sequential removal of red cells

Processing of tissues is an essential element in the production of viable and usable stem cells without contamination and unnecessary stimulation of the cells.

CordSlices
Processing slices of Umbilical Cord to harvest Wharton’s Jelly

Processing of physical tissue is different from processing fluidic tissue (Eg., peripheral blood) and requires processes without heat or trauma to the tissue.


Cell Characterisation
Characterisation of Mesenchymal Stem Cells. Collaboration with F.Mallein-Gerin, Lyon 1.
Characterisation of Mesenchymal Stem Cells. Collaboration with F.Mallein-Gerin, Lyon 1.

Harvested selected stem and progenitor cell populations require sophisticated examination from the point of harvest through to final use.

Cord blood-derived embryonic-like cells
Cord blood-derived embryonic-like cells

Such characterisation has allowed development of highly sophisticated techniques to harvest extremely rare cell populations such as the Cord Blood-derived Embryonic-like Cells (CBE)


Cell Manipulation
Rotating 3D culture system in collaboration with Synthecon Corp, Houston, Texas, using technology from NASA
Rotating 3D culture system in collaboration with Synthecon Corp, Houston, Texas, using technology from NASA

Rotating culture works to counteract natural gravity-based influences, such as basal adherence and allows cell networks to form which better resemble the human system.

Rotating fused air-liquid interface
Rotating fused air-liquid interface

Cell Differentiation
Neurofilamentous
Neurofilamentous

A particular speciality of our researchers is defined differentiation, particularly without animal products.

Mid level Neural
Mid-level neural network

Cellular interactions between different cell types can therefore be controlled.

Neural scaffold
3D neural niche

GMP Design and GMP processing tools

CTIBIOTECH staff have designed, created and implemented several GMP cell bioprocessing centres in both the academic and commercial sectors. These GMP centres have been used for both research and human clinical therapies.

3D neural macro-network on scaffold
3D neural macro-network on scaffold
CTIBIOTECH has strong academic and company partnerships in this area leading to both commercial products and clinical trials. For more information contact us here

DISCLAIMER: CTIBIOTECH does not carry out human therapies except as part of specific ongoing and government/hospital approved projects. We do not offer generalized stem cell therapies to specific patients. CTIBIOTECH recommends all patients to seek qualified medical advice from government-registered physicians in their home country.
 

 

COMPANY PROFILE

CTIBIOTECH aims to maximize the potential of tissues created by stem cell technologies and biopsies from cancer and skin for human therapeutic benefit

Read More

NEWS

Read about the latest CTIBIOTECH developments *LATEST* October 2016, CTIBIOTECH will be present in Japan for the BIOJAPAN international meeting

Read more here

SEARCH

Copyright © 2023 · CTIBIOTECH - All rights reserved. Log in